Amycretin: The Oral Obesity Drug and Gut Health Implications

The holy grail of GLP-1 drug development has always been a pill. Injectable medications work — but compliance drops, injection anxiety is real, and weekly injections are a significant lifestyle burden for many patients. Oral semaglutide (Rybelsus) was a step in this direction, but its low bioavailability (~1%) limits the dose that can realistically be delivered orally. Now Novo Nordisk has unveiled amycretin — an oral co-agonist that activates both the amylin and GLP-1 receptors in a single molecule designed specifically for oral delivery. Early trial results show remarkable efficacy: up to 13% weight loss in short-term Phase 1 trials. But for people with SIBO and gut motility concerns, an oral version of a dual amylin/GLP-1 agonist raises specific questions. What does oral delivery mean for GI tract exposure? Is the gut side effect profile better or worse than injectables? And how does direct GI tract contact change the risk landscape? This article breaks down everything we know so far.

What Is Amycretin and What Makes It Different?

Amycretin is a single-molecule oral co-agonist that simultaneously activates both the GLP-1 receptor and the amylin receptor. This distinguishes it from CagriSema, which combines two separate molecules (cagrilintide and semaglutide) in a fixed-dose injection. By engineering both activities into one molecule optimized for oral absorption, Novo Nordisk is attempting to capture the weight loss synergy of dual amylin/GLP-1 agonism in a convenient pill form. The compound was specifically engineered with oral bioavailability in mind — using structural modifications that improve stability against digestive enzymes and facilitate gastrointestinal absorption.

Early Phase 1 data published in 2024 in The New England Journal of Medicine showed that amycretin at 50mg once daily produced approximately 13.1% body weight reduction over 12 weeks in obese adults without diabetes. This is an extraordinary result for a 12-week trial — for context, semaglutide produces approximately 5-6% weight loss at 12 weeks. The results excited the obesity medicine field, though the usual cautions apply: Phase 1 trials are small, short, and not designed to capture long-term efficacy or safety comprehensively. Phase 2 trials with longer follow-up are now underway.

The Oral Delivery Breakthrough: What It Actually Means

Making a peptide drug work orally is a significant pharmacological challenge. Peptides — chains of amino acids — are normally digested in the stomach and small intestine before they can be absorbed. Insulin, GLP-1, and amylin all fail as oral drugs without special formulation technology. Oral semaglutide (Rybelsus) uses a SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) absorption enhancer that transiently disrupts the gastric mucosal barrier to facilitate absorption — but even so, less than 1% of the dose reaches the bloodstream. This means Rybelsus must be taken at a 3-14mg dose to achieve effects comparable to 0.25-1mg injectable semaglutide.

Amycretin uses a different oral delivery approach. While Novo Nordisk has not disclosed all formulation details, the compound's structure incorporates modifications that improve resistance to proteolytic degradation and enhance mucosal permeability. Bioavailability is still low compared to injectables — the effective systemic fraction is likely in the 1-5% range — but the molecule is engineered to be potent enough at the receptor level that even this fraction produces meaningful pharmacological effects. This is the 'oral bioavailability breakthrough' the drug represents: not high absorption, but sufficient potency combined with adequate absorption to drive clinical effects.

What Oral Delivery Means for Your GI Tract

Here is where oral amycretin gets specifically important for gut health. When a drug is swallowed, it passes through the esophagus, stomach, small intestine, and large intestine before the unabsorbed fraction is excreted. The fraction that is absorbed enters the bloodstream and circulates systemically. But for gut-active drugs, there is an additional layer of complexity: the drug can have direct pharmacological effects on gut tissue before, during, and after absorption. For oral semaglutide, this direct gut exposure is thought to contribute to higher rates of upper GI symptoms (nausea, stomach pain) compared to injectable semaglutide at equivalent systemic doses.

For amycretin, the oral route means that GLP-1 and amylin receptors in the gut lining, enteric nervous system, and gut-associated immune tissue are directly exposed to the drug as it transits the GI tract. This is not necessarily bad — GLP-1 receptors on intestinal L-cells and enteric neurons regulate motility and secretion, and local activation may produce different effects than purely systemic activation. But for SIBO patients whose gut receptors are already dysregulated, direct luminal drug exposure adds a layer of direct GI pharmacology on top of the systemic effects.

GI Side Effect Profile from Early Trials

The Phase 1 amycretin trial reported GI adverse events consistent with the drug class but with some distinct characteristics. Nausea was the most common adverse event, reported in approximately 45-50% of participants across active dose groups. Vomiting occurred in approximately 20% of participants. Notably, the dose-response relationship for GI side effects was steep — higher doses produced substantially more nausea and vomiting, consistent with the strong potency of the compound. Constipation rates in Phase 1 data were approximately 15-20%.

Comparing directly to injectable CagriSema is difficult because the Phase 1 trial was 12 weeks versus CagriSema's 68-week Phase 3 trials, and the dose ranges are not directly comparable. What the data does show is that amycretin's GI profile is roughly in line with injectable dual amylin/GLP-1 agents at comparable effective doses — high enough to warrant careful attention in motility-sensitive patients. The hope that oral delivery might mean 'gentler' GI effects appears not to be supported by Phase 1 data; the systemic drug exposure and receptor activation are potent enough that GI effects are substantial regardless of the route.

The SIBO Risk Question: Inferring from Mechanism

No published data directly addresses SIBO risk with amycretin. The drug is in Phase 2 trials, and SIBO-specific outcomes are not typically included in obesity drug trials. However, the mechanistic case for SIBO risk is straightforward: amycretin activates both the GLP-1 receptor and the amylin receptor, both of which independently delay gastric emptying through separate neural pathways. The combined motility effect is almost certainly additive, consistent with what we see with injectable CagriSema. Small bowel transit impairment and MMC suppression follow as downstream consequences.

What remains genuinely unknown is whether direct luminal exposure to amycretin adds any additional gut effect beyond the systemic motility consequences. GLP-1 receptors are expressed on enterocytes and enteric neurons — luminal drug exposure could in theory directly modulate peristalsis locally in addition to the systemic effects. This is an important research question that the current trial program is not designed to answer. For patients with SIBO or motility disorders, this uncertainty is another reason to approach amycretin cautiously once it reaches the market.

**Disclaimer:** This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any new treatment or making changes to your existing treatment plan.